NFlection Therapeutics

Recent Finacing

Series A

Recent Raise

$20M

NFlection Therapeutics develops topical soft MEK inhibitors that degrade systemically to treat cutaneous NF1 lesions and RASopathy-related skin conditions; NFX-179 Gel is in a Phase 2a randomized trial.

Founded 2014

Massachusetts, United States

1-10

Private

nflectionrx.com

Highlights

Focus Areas

Biotechnology

Medical

Pharmaceutical

Therapeutics

Recent Investors

Financials

$20M

Total Raised

1

Funding round

2

Investors

Team

Upgrade to view the team

See the team members at NFlection Therapeutics.